{"AllianceGenome": "10261", "HGNC": "10261", "MIM": "165020", "_id": "6098", "_version": 1, "accession": {"genomic": ["AH002964.2", "AL132671.20", "CH471051.2", "CP068272.2", "KF458262.1", "NC_000006.12", "NC_060930.1", "NG_033929.1", "Z98880.1"], "protein": ["AAA36580.1", "AAA60277.1", "AAA60278.1", "EAW48208.1", "EAW48209.1", "NP_001365820.1", "NP_001365831.1", "NP_002935.2", "P08922.3", "XP_006715611.1", "XP_011534351.1", "XP_011534352.1", "XP_011534353.1", "XP_011534355.1", "XP_011534356.1", "XP_011534357.1", "XP_011534358.1", "XP_011534359.1", "XP_011534360.1", "XP_016866661.1", "XP_016866662.1", "XP_047275187.1", "XP_047275188.1", "XP_054212147.1", "XP_054212148.1", "XP_054212149.1", "XP_054212150.1", "XP_054212151.1", "XP_054212152.1", "XP_054212153.1", "XP_054212154.1", "XP_054212155.1", "XP_054212156.1", "XP_054212157.1", "XP_054212158.1", "XP_054212159.1", "XP_054212160.1"], "rna": ["BC144556.1", "LC119066.1", "LC119067.1", "LC119068.1", "LC119069.1", "LC119070.1", "LC119071.1", "M13880.1", "M34353.1", "NM_001378891.1", "NM_001378902.1", "NM_002944.3", "XM_006715548.5", "XM_011536049.3", "XM_011536050.3", "XM_011536051.3", "XM_011536053.3", "XM_011536054.3", "XM_011536055.3", "XM_011536056.3", "XM_011536057.4", "XM_011536058.3", "XM_017011172.2", "XM_017011173.2", "XM_047419231.1", "XM_047419232.1", "XM_054356172.1", "XM_054356173.1", "XM_054356174.1", "XM_054356175.1", "XM_054356176.1", "XM_054356177.1", "XM_054356178.1", "XM_054356179.1", "XM_054356180.1", "XM_054356181.1", "XM_054356182.1", "XM_054356183.1", "XM_054356184.1", "XM_054356185.1"], "translation": [{"protein": "XP_011534357.1", "rna": "XM_011536055.3"}, {"protein": "XP_054212157.1", "rna": "XM_054356182.1"}, {"protein": "AAA36580.1", "rna": "M13880.1"}, {"protein": "XP_054212151.1", "rna": "XM_054356176.1"}, {"protein": "AAA60278.1", "rna": "M34353.1"}, {"protein": "XP_054212159.1", "rna": "XM_054356184.1"}, {"protein": "XP_054212153.1", "rna": "XM_054356178.1"}, {"protein": "XP_054212147.1", "rna": "XM_054356172.1"}, {"protein": "XP_016866662.1", "rna": "XM_017011173.2"}, {"protein": "XP_054212150.1", "rna": "XM_054356175.1"}, {"protein": "XP_047275187.1", "rna": "XM_047419231.1"}, {"protein": "XP_054212149.1", "rna": "XM_054356174.1"}, {"protein": "NP_001365831.1", "rna": "NM_001378902.1"}, {"protein": "XP_054212158.1", "rna": "XM_054356183.1"}, {"protein": "XP_047275188.1", "rna": "XM_047419232.1"}, {"protein": "XP_054212156.1", "rna": "XM_054356181.1"}, {"protein": "XP_054212160.1", "rna": "XM_054356185.1"}, {"protein": "XP_011534351.1", "rna": "XM_011536049.3"}, {"protein": "XP_054212154.1", "rna": "XM_054356179.1"}, {"protein": "XP_011534360.1", "rna": "XM_011536058.3"}, {"protein": "NP_001365820.1", "rna": "NM_001378891.1"}, {"protein": "NP_002935.2", "rna": "NM_002944.3"}, {"protein": "XP_011534353.1", "rna": "XM_011536051.3"}, {"protein": "XP_011534352.1", "rna": "XM_011536050.3"}, {"protein": "XP_006715611.1", "rna": "XM_006715548.5"}, {"protein": "XP_011534356.1", "rna": "XM_011536054.3"}, {"protein": "XP_011534358.1", "rna": "XM_011536056.3"}, {"protein": "XP_011534355.1", "rna": "XM_011536053.3"}, {"protein": "XP_016866661.1", "rna": "XM_017011172.2"}, {"protein": "XP_054212148.1", "rna": "XM_054356173.1"}, {"protein": "XP_054212152.1", "rna": "XM_054356177.1"}, {"protein": "XP_054212155.1", "rna": "XM_054356180.1"}, {"protein": "XP_011534359.1", "rna": "XM_011536057.4"}]}, "alias": ["MCF3", "ROS", "c-ros-1"], "ec": "2.7.10.1", "ensembl": {"gene": "ENSG00000047936", "protein": ["ENSP00000357493", "ENSP00000357494", "ENSP00000384647"], "transcript": ["ENST00000368507", "ENST00000368508", "ENST00000403284"], "translation": [{"protein": "ENSP00000357494", "rna": "ENST00000368508"}, {"protein": "ENSP00000357493", "rna": "ENST00000368507"}, {"protein": "ENSP00000384647", "rna": "ENST00000403284"}], "type_of_gene": "protein_coding"}, "entrezgene": "6098", "exac": {"_license": "http://bit.ly/2H9c4hg", "all": {"exp_lof": 77.5410834757, "exp_mis": 654.474950462, "exp_syn": 269.23007841, "lof_z": 0.735823167236621, "mis_z": -3.56621057877884, "mu_lof": 5.35229445332e-06, "mu_mis": 5.68523074554e-05, "mu_syn": 2.24487572446e-05, "n_lof": 71.0, "n_mis": 841.0, "n_syn": 330.0, "p_li": 1.78016845315113e-44, "p_null": 0.999994848110714, "p_rec": 5.15188928587586e-06, "syn_z": -2.29602271961926}, "bp": 7044, "cds_end": 117746819, "cds_start": 117609654, "n_exons": 43, "nonpsych": {"exp_lof": 69.3109488971, "exp_mis": 591.491787331, "exp_syn": 242.807992328, "lof_z": 0.744467432340636, "mis_z": -3.18360285680874, "mu_lof": 5.35229445332e-06, "mu_mis": 5.68523074554e-05, "mu_syn": 2.24487572446e-05, "n_lof": 63.0, "n_mis": 745.0, "n_syn": 290.0, "p_li": 2.86094070813951e-39, "p_null": 0.999970735180593, "p_rec": 2.92648194066958e-05, "syn_z": -1.90677905750727}, "nontcga": {"exp_lof": 71.2528788138, "exp_mis": 602.032076215, "exp_syn": 247.606767324, "lof_z": 0.847599024467859, "mis_z": -3.08568754763911, "mu_lof": 5.35229445332e-06, "mu_mis": 5.68523074554e-05, "mu_syn": 2.24487572446e-05, "n_lof": 64.0, "n_mis": 754.0, "n_syn": 302.0, "p_li": 1.44818186106583e-39, "p_null": 0.999959011695111, "p_rec": 4.09883048888515e-05, "syn_z": -2.1886964568446}, "transcript": "ENST00000368508.3"}, "exons": [{"cdsend": 117425656, "cdsstart": 117288491, "chr": "6", "position": [[117287352, 117288802], [117300973, 117301137], [117308793, 117308928], [117310080, 117310281], [117311019, 117311117], [117317142, 117317272], [117318187, 117318252], [117319867, 117320030], [117321258, 117321394], [117324331, 117324415], [117326223, 117326414], [117329328, 117329446], [117337171, 117337340], [117341134, 117341311], [117341399, 117341632], [117342399, 117342544], [117344059, 117344262], [117352989, 117353169], [117356628, 117356915], [117357803, 117358009], [117359808, 117360011], [117360341, 117360405], [117362602, 117362865], [117365059, 117365204], [117365580, 117365741], [117366075, 117366293], [117379058, 117379159], [117383316, 117383508], [117385682, 117385861], [117386888, 117386999], [117387779, 117387992], [117389349, 117389846], [117393223, 117393321], [117394161, 117394346], [117394615, 117394738], [117396187, 117396264], [117396914, 117397116], [117403138, 117403277], [117404279, 117404428], [117409581, 117409642], [117414518, 117414545], [117416257, 117416317], [117418461, 117418506], [117425533, 117425942]], "strand": -1, "transcript": "NM_001378891", "txend": 117425942, "txstart": 117287352}, {"cdsend": 117425656, "cdsstart": 117288491, "chr": "6", "position": [[117287352, 117288802], [117300973, 117301137], [117308793, 117308928], [117310080, 117310281], [117311019, 117311117], [117317142, 117317272], [117318187, 117318252], [117319867, 117320030], [117321258, 117321394], [117324331, 117324415], [117326223, 117326414], [117329328, 117329446], [117337171, 117337340], [117341134, 117341311], [117341399, 117341632], [117342399, 117342544], [117344059, 117344262], [117352989, 117353166], [117356628, 117356915], [117357803, 117358009], [117359808, 117360011], [117360341, 117360405], [117362602, 117362865], [117365059, 117365204], [117365580, 117365741], [117366075, 117366290], [117379058, 117379159], [117383316, 117383508], [117385682, 117385861], [117386888, 117386999], [117387779, 117387992], [117389349, 117389846], [117393223, 117393321], [117394161, 117394346], [117394615, 117394738], [117396187, 117396264], [117396914, 117397116], [117403138, 117403277], [117404279, 117404428], [117409581, 117409642], [117414518, 117414545], [117416257, 117416317], [117418461, 117418506], [117425533, 117425942]], "strand": -1, "transcript": "NM_001378902", "txend": 117425942, "txstart": 117287352}, {"cdsend": 117425656, "cdsstart": 117288491, "chr": "6", "position": [[117287352, 117288802], [117300973, 117301137], [117308793, 117308928], [117310080, 117310281], [117311019, 117311117], [117317142, 117317272], [117318187, 117318252], [117319867, 117320030], [117321258, 117321394], [117324331, 117324415], [117326223, 117326414], [117329328, 117329446], [117337171, 117337340], [117341134, 117341311], [117341399, 117341632], [117342399, 117342544], [117344059, 117344262], [117352989, 117353169], [117356628, 117356915], [117357803, 117358009], [117359808, 117360011], [117360341, 117360405], [117362602, 117362865], [117365059, 117365204], [117365580, 117365741], [117366075, 117366290], [117379058, 117379159], [117383316, 117383508], [117385682, 117385861], [117386888, 117386999], [117387779, 117388034], [117389349, 117389846], [117393223, 117393321], [117394161, 117394346], [117394615, 117394738], [117396187, 117396264], [117396914, 117397116], [117403138, 117403277], [117404279, 117404428], [117409581, 117409642], [117416257, 117416317], [117418461, 117418506], [117425533, 117425942]], "strand": -1, "transcript": "NM_002944", "txend": 117425942, "txstart": 117287352}], "exons_hg19": [{"cdsend": 117746819, "cdsstart": 117609654, "chr": "6", "position": [[117608515, 117609965], [117622136, 117622300], [117629956, 117630091], [117631243, 117631444], [117632182, 117632280], [117638305, 117638435], [117639350, 117639415], [117641030, 117641193], [117642421, 117642557], [117645494, 117645578], [117647386, 117647577], [117650491, 117650609], [117658334, 117658503], [117662297, 117662474], [117662562, 117662795], [117663562, 117663707], [117665222, 117665425], [117674152, 117674332], [117677791, 117678078], [117678966, 117679172], [117680971, 117681174], [117681504, 117681568], [117683765, 117684028], [117686222, 117686367], [117686743, 117686904], [117687238, 117687456], [117700221, 117700322], [117704479, 117704671], [117706845, 117707024], [117708051, 117708162], [117708942, 117709155], [117710512, 117711009], [117714386, 117714484], [117715324, 117715509], [117715778, 117715901], [117717350, 117717427], [117718077, 117718279], [117724301, 117724440], [117725442, 117725591], [117730744, 117730805], [117735681, 117735708], [117737420, 117737480], [117739624, 117739669], [117746696, 117747105]], "strand": -1, "transcript": "NM_001378891", "txend": 117747105, "txstart": 117608515}, {"cdsend": 117746819, "cdsstart": 117609654, "chr": "6", "position": [[117608515, 117609965], [117622136, 117622300], [117629956, 117630091], [117631243, 117631444], [117632182, 117632280], [117638305, 117638435], [117639350, 117639415], [117641030, 117641193], [117642421, 117642557], [117645494, 117645578], [117647386, 117647577], [117650491, 117650609], [117658334, 117658503], [117662297, 117662474], [117662562, 117662795], [117663562, 117663707], [117665222, 117665425], [117674152, 117674329], [117677791, 117678078], [117678966, 117679172], [117680971, 117681174], [117681504, 117681568], [117683765, 117684028], [117686222, 117686367], [117686743, 117686904], [117687238, 117687453], [117700221, 117700322], [117704479, 117704671], [117706845, 117707024], [117708051, 117708162], [117708942, 117709155], [117710512, 117711009], [117714386, 117714484], [117715324, 117715509], [117715778, 117715901], [117717350, 117717427], [117718077, 117718279], [117724301, 117724440], [117725442, 117725591], [117730744, 117730805], [117735681, 117735708], [117737420, 117737480], [117739624, 117739669], [117746696, 117747105]], "strand": -1, "transcript": "NM_001378902", "txend": 117747105, "txstart": 117608515}, {"cdsend": 117746819, "cdsstart": 117609654, "chr": "6", "position": [[117608515, 117609965], [117622136, 117622300], [117629956, 117630091], [117631243, 117631444], [117632182, 117632280], [117638305, 117638435], [117639350, 117639415], [117641030, 117641193], [117642421, 117642557], [117645494, 117645578], [117647386, 117647577], [117650491, 117650609], [117658334, 117658503], [117662297, 117662474], [117662562, 117662795], [117663562, 117663707], [117665222, 117665425], [117674152, 117674332], [117677791, 117678078], [117678966, 117679172], [117680971, 117681174], [117681504, 117681568], [117683765, 117684028], [117686222, 117686367], [117686743, 117686904], [117687238, 117687453], [117700221, 117700322], [117704479, 117704671], [117706845, 117707024], [117708051, 117708162], [117708942, 117709197], [117710512, 117711009], [117714386, 117714484], [117715324, 117715509], [117715778, 117715901], [117717350, 117717427], [117718077, 117718279], [117724301, 117724440], [117725442, 117725591], [117730744, 117730805], [117737420, 117737480], [117739624, 117739669], [117746696, 117747105]], "strand": -1, "transcript": "NM_002944", "txend": 117747105, "txstart": 117608515}], "generif": [{"pubmed": 15235104, "text": "Results show that c-ros expression in the human epididymis differs from that in mice and suggest that the unusual morphology of the human epididymis may reflect species differences in gene expression along the excurrent duct."}, {"pubmed": 15456853, "text": "inactivation of Ros by SHP-1-mediated dephosphorylation plays a role in the regulation of complex stability"}, {"pubmed": 16175505, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 16761743, "text": "bcl2 and ROS1 oncogene expression in meningiomas are not concurrent and neither can be ascribed to any histologic subtype or grade of tumor."}, {"pubmed": 17275003, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17275003, "text": "the G --> A polymorphism of ROS1 genotype was independently associated with in-stent restenosis in a Japanese population"}, {"pubmed": 17967605, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 17975119, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18097620, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18097620, "text": "These results suggest that polymorphisms of ABCA1 and ROS1 are determinants of blood pressure and the development of hypertension in Japanese individuals."}, {"pubmed": 18506375, "text": "Data show that genotypes for the G-->A (Asp2213Asn) polymorphism (rs529038) of ROS1 was associated (P<0.05) with the prevalence of atherothrombotic cerebral infarction."}, {"pubmed": 18566305, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 18676680, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19023099, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19056482, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19170196, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 19578796, "text": "Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 19625176, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19692168, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19709766, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19863298, "text": "Observational study of gene-disease association. (HuGE Navigator)"}, {"pubmed": 19863298, "text": "findings do not support the hypothesis that ROS1 rs529038 polymorphism is an important contributing factor in the etiology of CAD in the Greek population"}, {"pubmed": 20379614, "text": "Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"}, {"pubmed": 21253578, "text": "identification of ROS tyrosine kinase fusions in cholangiocarcinoma"}, {"pubmed": 22215748, "text": "ROS1 rearrangement defines a molecular subset of NSCLC with distinct clinical characteristics that are similar to those observed in patients with ALK-rearranged NSCLC."}, {"pubmed": 22327623, "text": "we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas"}, {"pubmed": 22585869, "text": "This study not only identifies ROS1 gene rearrangement as an additional driver mutation in NSCLC."}, {"pubmed": 22617245, "text": "ROS1 translocation is associated with lung cancer."}, {"pubmed": 22659450, "text": "Expression of CD74-ROS in noninvasive NSCLC cell lines readily conferred invasive properties that paralleled the acquisition of E-Syt1 phosphorylation."}, {"pubmed": 22661537, "text": "NSCLC tumors with ROS1 rearrangements are uncommon in the Chinese population and represent a distinct entity of carcinomas."}, {"pubmed": 22915320, "text": "These data further support functional roles of aberrant ROS1 protein in tumor progression of non-small cell lung carcinoma."}, {"pubmed": 23292247, "text": "Phosphorylated ROS1 activates MSK1 via Erk1/2 in the MAPK pathway, which then induces modifications to histone residues that regulate gene expression by 14-3-3 protein recruitment, leading to a lack of control of breast cancer cell proliferation."}, {"pubmed": 23400546, "text": "SLC34A2-ROS1 rearrangement was identified in GC, and the results provide a rationale for investigating the clinical efficacy of ROS1 inhibitors in this unique molecular subset of GC"}, {"pubmed": 23401445, "text": "ROS1 gene was first identified as an oncogene in NSCLC through a phosphoproteomic screen, leveraging the fact that oncogenic kinases should be highly phosphorylated proteins."}, {"pubmed": 23415111, "text": "Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia."}, {"pubmed": 23426121, "text": "All ROS1 fusion-positive lung tumors lacked alteration of EGFR, KRAS, HER2, ALK, and RET genes."}, {"pubmed": 23514723, "text": "ROS1 fusion-negative lung cancer patients may have a better survival than ROS1 fusion-positive patients."}, {"pubmed": 23549810, "text": "ROS1 expression is significantly lower in proportion to higher histologic grade, higher mitotic counts, lower estrogen receptor expression, and a higher Ki-67 proliferation index in invasive ductal carcinoma of the breast."}, {"pubmed": 23719267, "text": "Targeting ROS1 fusion proteins with the small-molecule inhibitor crizotinib is showing promise as an effective therapy in patients with NSCLC whose tumors are positive for these genetic abnormalities."}, {"pubmed": 23788756, "text": "The frequency of ROS1 rearrangements in clinically selected patients is higher than that reported for unselected patients."}, {"pubmed": 23810364, "text": "ROS1 gene rearrangements are associated with metastatic non--small-cell lung cancer."}, {"pubmed": 23887156, "text": "Immunohistochemical ROS1 protein expression in lung adenocarcinoma is 100% sensitive and 92% specific for ROS1 rearrangements by fluorescence in situ hybridization."}, {"pubmed": 24128715, "text": "ROS1 rearrangement is associated with non-small-cell lung cancer."}, {"pubmed": 24345493, "text": "significance of ROS1 rearrangements in non-small cell lung cancer"}, {"pubmed": 24349229, "text": "These results suggest that co-inhibition of ROS1 and EGFR may be an effective strategy to combat resistance to targeted therapy in some ROS1 fusion-positive non-small cell lung cancer patients."}, {"pubmed": 24456475, "text": "ROS1 translocations are rare events in resected non-small-cell lung cancers from Caucasian patients"}, {"pubmed": 24462463, "text": "poorer disease-free survival in fusion-positive lung adenocarcinoma patients after curative surgery"}, {"pubmed": 24629636, "text": "ALK, ROS1 and RET fusions are associated with pathological features of lung adenocarcinoma and are more prevalent in solid-predominant adenocarcinoma."}, {"pubmed": 24760415, "text": "Data show that translocations and amplifications of ROS1 gene occur at a similarly low rate in lung cancer brain metastases as reported for primary tumors"}, {"pubmed": 24999209, "text": "None of 268 gliomas analysed showed the FIG-ROS1(L) rearrangement"}, {"pubmed": 25230898, "text": "EZR-ROS1 fusion gene is associated with response to therapy in metastatic mediastinum lymph node from a non-small cell lung cancer."}, {"pubmed": 25231053, "text": "Six out of 65 (9%) BTC patients were positive for the FIG-ROS1 fusion, comprising two out of 14 (14%) gallbladder carcinoma (GBC) patients and four out of 25 (16%) extrahepatic cholangiocarcinoma (ECC) patients."}, {"pubmed": 25351743, "text": "We developed a comprehensive model of acquired resistance to ROS1 inhibitors in non-small cell lung cancer with ROS1 rearrangement and identified cabozantinib as a therapeutic strategy to overcome the resistance."}, {"pubmed": 25374304, "text": "ROS1 gene copy number gain status is more common in male patients and in cases with squamous histology in non small cell lung cancer"}, {"pubmed": 25401476, "text": "GPX1-dependent alterations in oxido-reductive stress promote ROS1 activation and mediate vascular remodeling."}, {"pubmed": 25612511, "text": "findings suggest that immunohistochemistry for ROS1 may be useful to support the diagnosis of a subset of inflammatory myofibroblastic tumors"}, {"pubmed": 25667280, "text": "lung cancer featuring a ROS1 rearrangement may be sensitive to protein kinase inhibitor crizotinib"}, {"pubmed": 25688157, "text": "Molecular changes associated with acquired crizotinib resistance in ROS1-rearranged non-small cell lung cancer are heterogeneous, including ROS1 tyrosine kinase mutations, EGFR activation, and epithelial-to-mesenchymal transition."}, {"pubmed": 25723109, "text": "inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions"}, {"pubmed": 25789833, "text": "Our findings show good correlation between FISH versus CISH in the detection of ALK and ROS1 rearrangements. FISH versus IHC showed good correlation in the detection of ALK rearrangements"}, {"pubmed": 25846554, "text": "ROS1 gene rearrangment is associated with drug resistance in non-small-cell lung cancer."}, {"pubmed": 25855381, "text": "our findings indicate that LADCs with ALK, RET, and ROS1 fusions develop exclusively via their dependence on these oncogene fusions."}, {"pubmed": 25868855, "text": "ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far."}, {"pubmed": 25905642, "text": "Of the 204 cases, 4 cases were confirmed with ROS1 rearrangement, but no RET rearrangement was detected. All 4 ROS1-rearranged cases were adenocarcinomas"}, {"pubmed": 25978031, "text": "The upregulation of ROS1 and DDR1 was confirmed at the protein level by western blot. Treatment with a potent and specific pyrazole ROS1 inhibitor in ROS1 overexpressing clones led to a sensitization of these cells to low concentrations of gefitinib."}, {"pubmed": 26149475, "text": "ROS1-rearranged adenocarcinoma exhibited distinct morphological and clinicopathological features."}, {"pubmed": 26152804, "text": "ALK and ROS1 rearrangements found in advanced non-small cell lung cancer patients"}, {"pubmed": 26310847, "text": "LIX1L is an RNA-binding protein, with implications for therapeutic approaches for targeting LIX1L in LIX1L-expressing cancer cells."}, {"pubmed": 26366867, "text": "ROS1 rearrangement was not identified in Glioblastoma Multiforme patients."}, {"pubmed": 26424208, "text": "Lung adenocarcinomas with RET and ROS1 fusions share many radiographic features."}, {"pubmed": 26475437, "text": "ROS1 protein expression was associated with well-differentiated histology and better survival in our patients with resected intrahepatic cholangiocarcinoma"}, {"pubmed": 26507842, "text": "ADAM9 and ROS1 are direct downstream targets of miR-33a"}, {"pubmed": 26647767, "text": "A subset of ALK-negative inflammatory myofibroblastic tumour (IMT) have rearrangement of ROS1, ETV6 or NTRK3 as a possible oncogenic mechanism."}, {"pubmed": 26673800, "text": "Overcome crizotinib resistance in a ROS1-rearranged cancer."}, {"pubmed": 26707143, "text": "curcumin and ABT-737 on HCC cells was investigated for the first time, to the best of our knowledge. It was found that curcumin markedly enhanced the antitumor effects of ABT-737 on HepG2 cells and activate ROS-ASK1-c-Jun N-terminal kinase pathway ."}, {"pubmed": 26783962, "text": "High prevalence of ROS1 copy number alterations are frequent in non-small cell lung cancer."}, {"pubmed": 26964870, "text": "ROS1-fusion genes act as a driver for the pathogenesis of lung adenocarcinoma."}, {"pubmed": 26973202, "text": "our study suggested that the prevalence of ALK, ROS1 and RET fusions is very rare in lung squamous cell carcinoma patients."}, {"pubmed": 27056998, "text": "Durable benefits with pemetrexed-based therapies in RET-rearranged lung cancers are comparable with ALK- and ROS1-rearranged lung cancers. When selecting therapies for patients with RET-rearranged lung cancers, pemetrexed-containing regimens should be considered."}, {"pubmed": 27121553, "text": "report adds the ZCCHC8-ROS1 fusion as oncogenic driver in GBM and supports the role of ROS1 activation in the pathogenesis of a subset of glioblastoma"}, {"pubmed": 27121721, "text": "ROS1 rearrangement was detected in 1.1% of CCA patients. Although rare, conduct of clinical trials using ROS1 inhibitors in these genetically unique patients is warranted."}, {"pubmed": 27136744, "text": "For intra-hepatic cholangiocarcinomas (IHCC)patients, ROS1, ALK and c-MET expression levels have prognostic significance on clinical outcomes. Although this finding may require further validation, it has led to proposal of a new stratification or enriched biomarker for future phase III trial of anti-EGFR therapy in IHCC"}, {"pubmed": 27153396, "text": "High CEP85L-ROS1 expression is associated with neoplasms."}, {"pubmed": 27256160, "text": "26 genes were found to fuse with ROS1 and different ROS1 fusions have distinct subcellular localization, suggesting that they may activate different substrates in vivo[review]"}, {"pubmed": 27328934, "text": "Given the results from the ROS1 cohort of the clinical trial PROFILE 1001, crizotinib represents a new treatment option and the first approved therapy for patients with metastatic non-small cell lung cancer whose tumors are ROS1 positive. Crizotinib demonstrated efficacy irrespective of prior treatment status."}, {"pubmed": 27401242, "text": "The ROS1 S1986Y/F and ALK C1156Y mutations are homologous and displayed similar sensitivity patterns to ALK/ROS1 TKIs."}, {"pubmed": 27575422, "text": "ROS1-positive metastatic lung adenocarcinomas frequently harbor concomitant oncogenic driver mutations."}, {"pubmed": 27635639, "text": "The frequencies of ALK, ROS1 and RET rearrangements are low in non-adenocarcinoma NSCLC patients. And their clinical characteristics are similar to those in lung adenocarcinoma. Fusions of the above 3 genes are not prognostic factor for non-adnocarcinoma NSCLC patients."}, {"pubmed": 27648828, "text": "Female, cribriform structure and presence of psammoma body were the three most powerful indicator of ROS1 rearrangement status, and predictive formula was helpful in screening ROS1-rearranged non-small-cell lung carcinomas, especially for ROS1 immunochemistry equivocal cases."}, {"pubmed": 27669657, "text": "C-ROS-1 is involved in Bone marrow-derived mesenchymal stem/stromal cell fate switching between osteogenesis and adipogenesis, mediated via PI3K/AKT/mTORC1 signalling."}, {"pubmed": 27708233, "text": "Compared with ROS1-negative advanced NSCLCs,ROS1-rearranged advanced NSCLCs were associated with a younger age at presentation. ROS1 rearrangements were not significantly associated with sex, smoking history, drinking history and metastatic sites."}, {"pubmed": 27864876, "text": "identified four genomic rearrangements involving the genes BRAF, RET, and ROS1"}, {"pubmed": 27912827, "text": "This review highlights treatment options, including clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations."}, {"pubmed": 28063177, "text": "ROS1 mutation is associated with response to chemotherapy in lung adenocarcinoma."}, {"pubmed": 28088512, "text": "ROS1 rearrangements rarely overlap with alterations in EGFR, KRAS, ALK, or other targetable oncogenes in NSCLC."}, {"pubmed": 28181564, "text": "the results from three transcriptome-based platforms (Nanostring Elements, Agena LungFusion panel and ThermoFisher NGS fusion panel) were compared to those obtained from ALK, ROS1 and RET Fluorescence In Situ Hybridization on 51 clinical specimens."}, {"pubmed": 28400043, "text": "Polymorphisms rs1333049 and rs10757278 are associated with SCD in men and rs499818 in the women aged over 50 years."}, {"pubmed": 28560674, "text": "Detection of Gene Rearrangements in Circulating Tumor Cells: Examples of ALK-, ROS1-, RET-Rearrangements in Non-Small-Cell Lung Cancer and ERG-Rearrangements in Prostate Cancer.("}, {"pubmed": 28743163, "text": "Studies suggest that the routine clinical use of fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC) may be replaced by emerging next-generation sequencing and digital, color-coded barcode technologies, which have the advantage of simultaneously evaluating anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) and epidermal growth factor receptor (EGFR) alterations in a single analysis."}, {"pubmed": 28759046, "text": "Findings highlight ROS1 as a candidate biomarker and therapeutic target for oral squamous cell carcinoma."}, {"pubmed": 28890346, "text": "MFA has a protective effect on alcohol-induced liver injury, which may be related to its antioxidant,anti-inflammatory,lipid-eliminating properties and its ability to regulate the NOX4/ROS-MAPK signalling pathway."}, {"pubmed": 28893136, "text": "The present study revealed the detailed inhibitory mechanism of loratinib as potent WT and G2032R mutated ROS1 inhibitor, which was expected to provide a basis for rational drug design"}, {"pubmed": 28952227, "text": "Detection of the gene status of EGFR, ROS1, and MET will facilitate screening more NSCL adenocarcinoma patients who might benefit from targeted therapy."}, {"pubmed": 29251734, "text": "in 14 ROS1+ lung adenocarcinoma cases, 9 rearrangements detected (gene partner: CD74 in 8 cases and SLC34A2 in 1)"}, {"pubmed": 29370427, "text": "ROS1 gene Rearrangement is associated with Metastatic Colorectal Cancer."}, {"pubmed": 29477381, "text": "CD74-ROS1 G2032R mutation mediated EMT phenotype by increasing the expression of Twist1, resulting in drug resistance. Combination of Twist1 silence and ROS1 inhibitor may provide a potent strategy to treat the ROS1(+) NSCLC patients with crizotinib resistance."}, {"pubmed": 29517860, "text": "CEP72-ROS1 is a novel ROS1 fusion variant in non-small cell lung cancer (NSCLC) discovered by next-generation sequencing and could be included in ROS1 detection assay, such as reverse transcription PCR."}, {"pubmed": 29617048, "text": "None of the genitourinary pseudosarcomatous myofibroblastic proliferations was found to harbour USP6 (0/12), ROS1 (0/8) or ETV6 (0/7) rearrangements"}, {"pubmed": 29623743, "text": "Study based on 47 tissue samples from spitzoid tumors revealed 2 BAP1-inactived cases. The absence of anomalous expression of translocation-related proteins ALK and ROS1 in this series, composed predominantly of low-grade/low-risk tumors, indicates that translocated spitzoid lesions may not be as prevalent as initially suggested, at least in some populations."}, {"pubmed": 29663378, "text": "C-ROS-1 promotes osteogenic differentiation of TWIST-1 haploinsufficient calvarial osteogenic progenitor cells."}, {"pubmed": 29704675, "text": "Patients with CD74-ROS1 fusion partners are associated with brain metastases in Non-Small Cell Lung Cancer."}, {"pubmed": 29883837, "text": "ROS1-positive NSCLC has distinct clinical characteristics, with an effective and durable response to both TKIs and pemetrexed-based chemotherapies."}, {"pubmed": 29945753, "text": "ROS1 gene rearrangement is associated with Non-Small-cell Lung Cancer."}, {"pubmed": 29981925, "text": "Brain metastases are common in treatment-naive stage IV ROS1-positive NSCLC, though the incidence does not differ from that in other oncogene cohorts."}, {"pubmed": 30107055, "text": "lung adenocarcinoma in Asian patients aged </=50 years had a higher gene mutation rate than in those aged >50 years, especially EML4-ALK and ROS1 fusion. Mutation analysis may be helpful in determining targeted therapy for the majority of these patients"}, {"pubmed": 30171048, "text": "CNS tumors should be specifically interrogated for these rare intrachromosomal 6q22 microdeletion events that generate actionable ROS1 fusions. ROS1 fusions in primary brain cancer may be amenable for clinical intervention with kinase inhibitors, and this holds the potential of novel treatment paradigms in these treatment-refractory cancer types, particularly in glioblastoma."}, {"pubmed": 30249502, "text": "Although rare, patients with ovarian serous carcinoma or serous borderline tumor may exhibit ROS1 gene rearrangement and ROS1 protein expression"}, {"pubmed": 30262706, "text": "The upstream breakpoint lies in the same region as the breakpoint of a fused gene SLC34A2-ROS1, which encodes a constitutive kinase in the lung cancer cell line HCC78 and nonsmall-cell lung cancer (NSCLC), suggesting that the deletion in this family is a hot spot for recombination, not only in cancer samples with somatic mutation, but also in PAM patients with germline genetic defects of SLC34A2."}, {"pubmed": 30350109, "text": "ROS1 is a tyrosine kinase that is closely related to anaplastic lymphoma kinase receptor and various ROS1 fusions might be present in a subset of pediatric gliomas, which could be targeted for therapy."}, {"pubmed": 30475455, "text": "In the largest consecutive routine Asian non-small cell lung cancer (NSCLC) cohort analyzed to date, we found that high PD-L1 expression frequently overlapped with ROS1 rearrangement, while it negatively correlated with EGFR mutations."}, {"pubmed": 30538120, "text": "ROS1 fusion oncoproteins exhibit differential activation of MAPK signaling according to subcellular localization, with ROS1 fusions localized to endosomes, the strongest activators of MAPK signaling."}, {"pubmed": 30543838, "text": "In multivariable analysis, the odds of a TEE were significantly higher for ROS1+ compared to EGFR+ and KRAS+ cohorts, the odds ratio (OR) was 2.44, with a 95% confidence interval of 1.31-4.57 (p = 0.005), and OR: 2.62, with a 95% confidence interval of 1.26-5.46 (p = 0.01), respectively."}, {"pubmed": 30565433, "text": "ROS1 gene rearrangements are associated with non-small cell lung cancer."}, {"pubmed": 30580372, "text": "Females were often inflicted by the EGFR mutations, especially for the exon 19 deletion and L858R mutation. There were significantly more ALK/ROS1 fusions in females compared to that in males and significantly more ALK/ROS1 fusions in patients <60 years old compared to patients older than 60 years of age. Exon 21 L858R and L861Q dominantly occurred in patients >/=60 years and exon 19 deletion in patients <60 years"}, {"pubmed": 30940295, "text": "our study demonstrates that ROS1(+) patients with various fusion partners show comparable efficacy to crizotinib."}, {"pubmed": 30943926, "text": "Findings suggest that the measurement of C-terminal ALK or ROS1 protein could be a reliable diagnostic method for each fusion in lung cancer."}, {"pubmed": 31053160, "text": "In conclusion, our study revealed that celastrol caused G2/M phase arrest and trigged apoptosis and autophagy by activating ROS/JNK signaling and blocking the Akt/mTOR signaling pathway"}, {"pubmed": 31349061, "text": "Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study."}, {"pubmed": 31361233, "text": "This is the first study from the Indian subcontinent to identify the frequency of ROS-1 re-arrangements and MET amplification in the Indian lung adenocarcinoma population. c-MET protein expression was identified in 33.33%, and ROS-1 protein expression was detected in 3.33% cases."}, {"pubmed": 31361613, "text": "Spitz Tumors With ROS1 Fusions: A Clinicopathological Study of 6 Cases, Including FISH for Chromosomal Copy Number Alterations and Mutation Analysis Using Next-Generation Sequencing."}, {"pubmed": 31392269, "text": "Rearrangements of ALK/ROS1 were quantified using circulating tumor cells (CTCs) mRNA and matched with those identified in biopsy specimens from 12 patients with late-stage non-small cell lung cancer. Moreover, CTC counts and copy numbers of ALK/ROS1 rearrangements could be used together for evaluating treatment responses and disease progression."}, {"pubmed": 31399568, "text": "DS-6051b is effective in treating ROS1- or NTRK-rearranged cancer in preclinical models, including crizotinib-resistant ROS1 positive cancer with secondary kinase domain mutations especially G2032R mutation which is highly resistant to crizotinib as well as lorlatinib and entrectinib, next generation ROS1 inhibitors."}, {"pubmed": 31447007, "text": "We provide confirmation that patients with 5' ROS1 deletions might respond to anti-ALK/ROS1 therapy by analogy with ALK."}, {"pubmed": 31584608, "text": "Crizotinib activity in patients with ROS1-translocated tumours was confirmed. In the c-MET-mutation and c-MET >/=6 copies cohorts, despite insufficient ORR after two cycles of crizotinib, there are signs of late response not sufficient to justify the development of crizotinib in this indication"}, {"pubmed": 31607443, "text": "ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)."}, {"pubmed": 31626289, "text": "GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors."}, {"pubmed": 31708389, "text": "Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer."}, {"pubmed": 31907296, "text": "Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas."}, {"pubmed": 32447492, "text": "ROS1 rearrangements seem to be very rare in biliary tract adenocarcinomas"}, {"pubmed": 32580101, "text": "Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer."}, {"pubmed": 32648475, "text": "Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer."}, {"pubmed": 32681682, "text": "Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study."}, {"pubmed": 32702569, "text": "Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study."}, {"pubmed": 32862201, "text": "Clinical, morphologic, and genomic findings in ROS1 fusion Spitz neoplasms."}, {"pubmed": 32871626, "text": "Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing."}, {"pubmed": 32881404, "text": "EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India."}, {"pubmed": 32928143, "text": "Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients."}, {"pubmed": 32979347, "text": "High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma."}, {"pubmed": 33038629, "text": "Functional coding/non-coding variants in EGFR, ROS1 and ALK genes and their role in liquid biopsy as a personalized therapy."}, {"pubmed": 33053439, "text": "Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma."}, {"pubmed": 33166862, "text": "High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1."}, {"pubmed": 33168793, "text": "Comprehensive analysis of ALK, ROS1 and RET rearrangements in locally advanced rectal cancer."}, {"pubmed": 33196586, "text": "Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma."}, {"pubmed": 33211628, "text": "The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non-Small-Cell Lung Cancer."}, {"pubmed": 33248323, "text": "Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC."}, {"pubmed": 33290717, "text": "Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date."}, {"pubmed": 33324391, "text": "ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer."}, {"pubmed": 33336398, "text": "Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases."}, {"pubmed": 33402590, "text": "FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience."}, {"pubmed": 33583243, "text": "Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer."}, {"pubmed": 33677892, "text": "[Clinicopathological significance in non-small cell lung cancer with mutations and co-mutations of EGFR, ALK and ROS1]."}, {"pubmed": 33683692, "text": "Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples."}, {"pubmed": 33685866, "text": "Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer."}, {"pubmed": 33760160, "text": "Cigarette smoke extract stimulates PCSK9 production in HepG2 cells via ROS/NFkappaB signaling."}, {"pubmed": 34033159, "text": "Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital."}, {"pubmed": 34310819, "text": "Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers."}, {"pubmed": 34322931, "text": "Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion."}, {"pubmed": 34449580, "text": "Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System."}, {"pubmed": 34536122, "text": "GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types."}, {"pubmed": 34558414, "text": "Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma."}, {"pubmed": 34686712, "text": "Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement."}, {"pubmed": 34884672, "text": "Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations."}, {"pubmed": 35081265, "text": "Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions."}, {"pubmed": 35303812, "text": "Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain."}, {"pubmed": 35634843, "text": "ROS1 altered breast cancers - a distinctive molecular subtype of PR- metastatic breast cancers: Expanding the scope of targeted therapeutics."}, {"pubmed": 36053834, "text": "ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer."}, {"pubmed": 36308382, "text": "SNP rs9387478 at ROS1-DCBLD1 Locus is Significantly Associated with Lung Cancer Risk and Poor Survival in Indian Population."}, {"pubmed": 36804622, "text": "ROS1 as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing."}, {"pubmed": 37237384, "text": "Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer."}, {"pubmed": 37511255, "text": "Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer."}, {"pubmed": 37579577, "text": "Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients."}, {"pubmed": 37587872, "text": "Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors."}, {"pubmed": 37856763, "text": "Inflammatory Myofibroblastic Tumor With ROS1 Gene Fusions in Children and Young Adolescents."}, {"pubmed": 38148635, "text": "CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells."}, {"pubmed": 38468443, "text": "RB1 loss induces quiescent state through downregulation of RAS signaling in mammary epithelial cells."}], "genomic_pos": {"chr": "6", "end": 117425942, "ensemblgene": "ENSG00000047936", "start": 117287353, "strand": -1}, "genomic_pos_hg19": {"chr": "6", "end": 117747018, "start": 117609463, "strand": -1}, "go": {"BP": [{"evidence": "IDA", "gocategory": "BP", "id": "GO:0001558", "pubmed": 16885344, "qualifier": "involved_in", "term": "regulation of cell growth"}, {"evidence": "ISS", "gocategory": "BP", "id": "GO:0002066", "qualifier": "involved_in", "term": "columnar/cuboidal epithelial cell development"}, {"evidence": "IDA", "gocategory": "BP", "id": "GO:0006468", "pubmed": 16885344, "qualifier": "involved_in", "term": "protein phosphorylation"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0007169", "qualifier": "involved_in", "term": "cell surface receptor protein tyrosine kinase signaling pathway"}, {"evidence": "IEA", "gocategory": "BP", "id": "GO:0007169", "qualifier": "involved_in", "term": "cell surface receptor protein tyrosine kinase signaling pathway"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0007275", "qualifier": "involved_in", "term": "multicellular organism development"}, {"evidence": "ISS", "gocategory": "BP", "id": "GO:0007283", "qualifier": "involved_in", "term": "spermatogenesis"}, {"evidence": "ISS", "gocategory": "BP", "id": "GO:0030154", "qualifier": "involved_in", "term": "cell differentiation"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0032006", "qualifier": "involved_in", "term": "regulation of TOR signaling"}, {"evidence": "IDA", "gocategory": "BP", "id": "GO:0032006", "pubmed": 16885344, "qualifier": "involved_in", "term": "regulation of TOR signaling"}, {"evidence": "IBA", "gocategory": "BP", "id": "GO:0033674", "qualifier": "involved_in", "term": "positive regulation of kinase activity"}, {"evidence": "ISS", "gocategory": "BP", "id": "GO:0070372", "qualifier": "involved_in", "term": "regulation of ERK1 and ERK2 cascade"}], "CC": [{"evidence": "IBA", "gocategory": "CC", "id": "GO:0005886", "qualifier": "is_active_in", "term": "plasma membrane"}, {"evidence": "TAS", "gocategory": "CC", "id": "GO:0016020", "pubmed": 3785223, "qualifier": "located_in", "term": "membrane"}, {"evidence": "IBA", "gocategory": "CC", "id": "GO:0043235", "qualifier": "part_of", "term": "receptor complex"}], "MF": [{"category": "MF", "evidence": "IDA", "id": "GO:0004713", "pubmed": 16885344, "qualifier": "enables", "term": "protein tyrosine kinase activity"}, {"category": "MF", "evidence": "IBA", "id": "GO:0004714", "qualifier": "enables", "term": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "MF", "evidence": "IPI", "id": "GO:0005515", "pubmed": [17416557, 32499443], "qualifier": "enables", "term": "protein binding"}, {"category": "MF", "evidence": "IEA", "id": "GO:0005524", "qualifier": "enables", "term": "ATP binding"}, {"category": "MF", "evidence": "IPI", "id": "GO:0019903", "pubmed": 16885344, "qualifier": "enables", "term": "protein phosphatase binding"}]}, "homologene": {"genes": [[7165, 1272261], [7227, 32039], [7955, 245951], [8364, 101733913], [9031, 396192], [9544, 715284], [9598, 472108], [9606, 6098], [9615, 484098], [9913, 100336768], [10090, 19886], [10116, 25346]], "id": 2207}, "interpro": [{"desc": "LDLR class B repeat", "id": "IPR000033", "short_desc": "LDLR_classB_rpt"}, {"desc": "Protein kinase domain", "id": "IPR000719", "short_desc": "Prot_kinase_dom"}, {"desc": "Serine-threonine/tyrosine-protein kinase, catalytic domain", "id": "IPR001245", "short_desc": "Ser-Thr/Tyr_kinase_cat_dom"}, {"desc": "Tyrosine-protein kinase, receptor class II, conserved site", "id": "IPR002011", "short_desc": "Tyr_kinase_rcpt_2_CS"}, {"desc": "Fibronectin type III", "id": "IPR003961", "short_desc": "FN3_dom"}, {"desc": "Tyrosine-protein kinase, active site", "id": "IPR008266", "short_desc": "Tyr_kinase_AS"}, {"desc": "Protein kinase-like domain superfamily", "id": "IPR011009", "short_desc": "Kinase-like_dom_sf"}, {"desc": "Six-bladed beta-propeller, TolB-like", "id": "IPR011042", "short_desc": "6-blade_b-propeller_TolB-like"}, {"desc": "Immunoglobulin-like fold", "id": "IPR013783", "short_desc": "Ig-like_fold"}, {"desc": "Protein kinase, ATP binding site", "id": "IPR017441", "short_desc": "Protein_kinase_ATP_BS"}, {"desc": "Tyrosine-protein kinase, catalytic domain", "id": "IPR020635", "short_desc": "Tyr_kinase_cat_dom"}, {"desc": "Fibronectin type III superfamily", "id": "IPR036116", "short_desc": "FN3_sf"}], "ipi": ["IPI00288965", "IPI00647703"], "map_location": "6q22.1", "name": "ROS proto-oncogene 1, receptor tyrosine kinase", "other_names": ["ROS proto-oncogene 1 , receptor tyrosine kinase", "c-ros oncogene 1 , receptor tyrosine kinase", "proto-oncogene c-Ros-1", "proto-oncogene tyrosine-protein kinase ROS", "transmembrane tyrosine-specific protein kinase", "v-ros avian UR2 sarcoma virus oncogene homolog 1"], "pantherdb": {"HGNC": "10261", "_license": "http://pantherdb.org/tou.jsp", "ortholog": [{"MGI": "97999", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 10090, "uniprot_kb": "Q78DX7"}, {"RGD": "3591", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 10116, "uniprot_kb": "Q63132"}, {"Gene": "ROS1", "ortholog_type": "O", "panther_family": "PTHR24416", "taxid": 9031, "uniprot_kb": "P08941"}, {"Ensembl": "ENSGALG00000014913", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 9031, "uniprot_kb": "F1NQL9"}, {"ZFIN": "ZDB-GENE-020506-1", "ortholog_type": "LDO", "panther_family": "PTHR24416", "taxid": 7955, "uniprot_kb": "F1QMJ7"}], "uniprot_kb": "P08922"}, "pathway": {"wikipathways": [{"id": "WP2431", "name": "Spinal Cord Injury"}, {"id": "WP3630", "name": "NAD metabolism, sirtuins and aging"}, {"id": "WP4790", "name": "FGF23 signaling in hypophosphatemic rickets and related disorders"}]}, "pdb": ["3ZBF", "4UXL", "7Z5W", "7Z5X"], "pfam": ["PF00041", "PF07714"], "pharmgkb": "PA34633", "pharos": {"target_id": 14317, "tdl": "Tclin"}, "pir": "A35512", "prosite": ["PS50011", "PS50853"], "reagent": {"GNF_Qia_hs-genome_v1_siRNA": [{"id": "GNF218465", "relationship": "is"}, {"id": "GNF255787", "relationship": "is"}, {"id": "GNF255788", "relationship": "is"}, {"id": "GNF255789", "relationship": "is"}, {"id": "GNF255790", "relationship": "is"}], "GNF_hs-druggable_lenti-shRNA": [{"id": "GNF092354", "relationship": "is"}, {"id": "GNF092355", "relationship": "is"}, {"id": "GNF092356", "relationship": "is"}], "GNF_hs-druggable_plasmid-shRNA": [{"id": "GNF052229", "relationship": "is"}, {"id": "GNF056998", "relationship": "is"}, {"id": "GNF061831", "relationship": "is"}], "GNF_hs-druggable_siRNA": [{"id": "GNF070375", "relationship": "is"}, {"id": "GNF070376", "relationship": "is"}], "GNF_hs-pkinase_IDT-siRNA": [{"id": "GNF166016", "relationship": "is"}, {"id": "GNF166017", "relationship": "is"}, {"id": "GNF166018", "relationship": "is"}, {"id": "GNF166019", "relationship": "is"}], "Invitrogen_IVTHSSIPKv2": [{"id": "GNF324022", "relationship": "is"}, {"id": "GNF324023", "relationship": "is"}], "NOVART_hs-genome_siRNA": [{"id": "GNF093086", "relationship": "is"}, {"id": "GNF132784", "relationship": "is"}]}, "refseq": {"genomic": ["NC_000006.12", "NC_060930.1", "NG_033929.1"], "protein": ["NP_001365820.1", "NP_001365831.1", "NP_002935.2", "XP_006715611.1", "XP_011534351.1", "XP_011534352.1", "XP_011534353.1", "XP_011534355.1", "XP_011534356.1", "XP_011534357.1", "XP_011534358.1", "XP_011534359.1", "XP_011534360.1", "XP_016866661.1", "XP_016866662.1", "XP_047275187.1", "XP_047275188.1", "XP_054212147.1", "XP_054212148.1", "XP_054212149.1", "XP_054212150.1", "XP_054212151.1", "XP_054212152.1", "XP_054212153.1", "XP_054212154.1", "XP_054212155.1", "XP_054212156.1", "XP_054212157.1", "XP_054212158.1", "XP_054212159.1", "XP_054212160.1"], "rna": ["NM_001378891.1", "NM_001378902.1", "NM_002944.3", "XM_006715548.5", "XM_011536049.3", "XM_011536050.3", "XM_011536051.3", "XM_011536053.3", "XM_011536054.3", "XM_011536055.3", "XM_011536056.3", "XM_011536057.4", "XM_011536058.3", "XM_017011172.2", "XM_017011173.2", "XM_047419231.1", "XM_047419232.1", "XM_054356172.1", "XM_054356173.1", "XM_054356174.1", "XM_054356175.1", "XM_054356176.1", "XM_054356177.1", "XM_054356178.1", "XM_054356179.1", "XM_054356180.1", "XM_054356181.1", "XM_054356182.1", "XM_054356183.1", "XM_054356184.1", "XM_054356185.1"], "translation": [{"protein": "XP_011534357.1", "rna": "XM_011536055.3"}, {"protein": "XP_054212157.1", "rna": "XM_054356182.1"}, {"protein": "XP_054212151.1", "rna": "XM_054356176.1"}, {"protein": "XP_054212159.1", "rna": "XM_054356184.1"}, {"protein": "XP_054212153.1", "rna": "XM_054356178.1"}, {"protein": "XP_054212147.1", "rna": "XM_054356172.1"}, {"protein": "XP_016866662.1", "rna": "XM_017011173.2"}, {"protein": "XP_054212150.1", "rna": "XM_054356175.1"}, {"protein": "XP_047275187.1", "rna": "XM_047419231.1"}, {"protein": "XP_054212149.1", "rna": "XM_054356174.1"}, {"protein": "NP_001365831.1", "rna": "NM_001378902.1"}, {"protein": "XP_054212158.1", "rna": "XM_054356183.1"}, {"protein": "XP_047275188.1", "rna": "XM_047419232.1"}, {"protein": "XP_054212156.1", "rna": "XM_054356181.1"}, {"protein": "XP_054212160.1", "rna": "XM_054356185.1"}, {"protein": "XP_011534351.1", "rna": "XM_011536049.3"}, {"protein": "XP_054212154.1", "rna": "XM_054356179.1"}, {"protein": "XP_011534360.1", "rna": "XM_011536058.3"}, {"protein": "NP_001365820.1", "rna": "NM_001378891.1"}, {"protein": "NP_002935.2", "rna": "NM_002944.3"}, {"protein": "XP_011534352.1", "rna": "XM_011536050.3"}, {"protein": "XP_011534353.1", "rna": "XM_011536051.3"}, {"protein": "XP_006715611.1", "rna": "XM_006715548.5"}, {"protein": "XP_011534356.1", "rna": "XM_011536054.3"}, {"protein": "XP_011534358.1", "rna": "XM_011536056.3"}, {"protein": "XP_011534355.1", "rna": "XM_011536053.3"}, {"protein": "XP_016866661.1", "rna": "XM_017011172.2"}, {"protein": "XP_054212148.1", "rna": "XM_054356173.1"}, {"protein": "XP_054212152.1", "rna": "XM_054356177.1"}, {"protein": "XP_054212155.1", "rna": "XM_054356180.1"}, {"protein": "XP_011534359.1", "rna": "XM_011536057.4"}]}, "reporter": {"HG-U133_Plus_2": ["207569_at", "244363_at"], "HG-U95Av2": "593_s_at", "HTA-2_0": "TC06004055.hg.1", "HuEx-1_0": ["2436526", "2881370", "2971267", "2981912", "3907234"], "HuGene-1_1": ["7920472", "8066513", "8115147", "8129134", "8130505", "8142468"], "HuGene-2_1": ["16919567", "17022996", "17025191"]}, "summary": "This proto-oncogene, highly-expressed in a variety of tumor cell lines, belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. The protein encoded by this gene is a type I integral membrane protein with tyrosine kinase activity. The protein may function as a growth or differentiation factor receptor. [provided by RefSeq, Jul 2008].", "symbol": "ROS1", "taxid": 9606, "type_of_gene": "protein-coding", "umls": {"cui": "C0812281"}, "unigene": "Hs.1041", "uniprot": {"Swiss-Prot": "P08922", "TrEMBL": ["H0Y3T9", "Q5H8Y1"]}, "wikipedia": {"url_stub": "ROS1 (gene)"}}